### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Bendele et al.

Serial No.: Not Yet Received

Group Art Unit No.: 1646

Filed:

July 17, 2001

Examiner: E. O'Hara

For:

COMBINATION THERAPY USING A TNF BINDING

PROTEIN FOR TREATING TNF-MEDIATED

DISEASES

Docket No.: A-430F

# PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Please amend the referenced application as follows:

### In the Specification

At page 1, line 3, insert the following paragraph:

This application is a divisional of application Serial No. 09/326,394 filed June 4, 1999, which is a continuation of PCT/US97/22733, filed December 8, 1997, which claims benefit to U.S. Provisional Serial No. 60/032,587, filed December 6, 1996, U.S. Provisional Serial No. 60/036,355, filed January 23, 1997, U.S. Provisional Serial No. 60/039,315, filed February 7, 1997 and U.S. Provisional Serial No. 60/052,023, filed July 9, 1997, all of which are hereby incorporated by reference.

## In the Claims

Please cancel claims 2-26 and insert the following new claims:

- The method of treatment of an acute or chronic inflammatory disease of Claim 1, which 27. comprises administering a TNF binding protein in combination with the prior, concurrent, or post-administration of a COX2 inhibitor.
  - 28. The method of treatment according to claim 27, wherein the COX2 inhibitor is celecoxib.

### **EXPRESS MAIL CERTIFICATE**

Express Mail mail labeling number	EL360689926US	Date of Deposit	July 17, 2001		
hereby certify that this paper or fee is b	eing deposited with the United States Po	ostal Service "Express Mail Post	Office to Addressee*	seprice under 37 CFR 1	10 on

se" service under 37 CFR 1 10 on the date

- 29. The method of treatment according to claim 27, wherein the acute or chronic inflammatory disease is a TNF-mediated disease.
- 30. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 31. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 90% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 32. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 95% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 33. The method of treatment according to claim 27, wherein said TNF binding protein comprises a sequence which is at least about 99% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 34. The method of treatment according to claim 27, wherein said TNF binding protein comprises an amino acid having a sequence of SEQ ID NO: 2.
- 35. The method of treatment according to claim 27, wherein said TNF binding protein comprises a deletion variant of SEQ ID NO: 2 having an N-terminal or C-terminal deletion.
- 36. The method of treatment according to claim 27, wherein said TNF binding protein is non-glycosylated.
- 37. The method of treatment according to claim 27, wherein said TNF binding protein is glycosylated.
- 38. The method of treatment according to claim 30, wherein an additional amino acid is added to the sequence of SEQ ID NO: 2 and the additional amino acid is an N-terminal methionine having the residue number "0".
- 39. The method of treatment according to claim 27, wherein said TNF binding protein is produced by recombinant DNA methods.
- 40. The method of treatment according to claim 27, wherein said inflammatory disease is an inflammatory disease of a joint.
- 41. The method of treatment according to claim 27, wherein said inflammatory disease is rheumatoid arthritis.

- 42. A dosage unit, comprising a COX2 inhibitor for the treatment of an acute or chronic inflammatory disease in a patient and a TNF binding protein, wherein said dosage unit allows for administration of the COX2 inhibitor prior, concurrent, or after administration of the TNF binding protein.
  - 43. The dosage unit according to claim 42, wherein the COX2 inhibitor is celecoxib.
- 44. The dosage unit according to claim 42, wherein the acute or chronic inflammatory disease is a TNF-mediated disease.
- 45. The dosage unit according to claim 42, wherein said TNF binding protein comprises a sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 46. The dosage unit according to claim 42, wherein said TNF binding protein comprises a sequence which is at least about 90% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 47. The dosage unit according to claim 42, wherein said TNF binding protein comprises a sequence which is at least about 95% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 48. The dosage unit according to claim 42, wherein said TNF binding protein comprises a sequence which is at least about 99% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 49. The dosage unit according to claim 42, wherein said TNF binding protein comprises an amino acid having a sequence of SEQ ID NO: 2.
- 50. The dosage unit according to claim 42, wherein said TNF binding protein comprises a deletion variant of SEQ ID NO: 2 having an N-terminal or C-terminal deletion.
  - 51. The dosage unit according to claim 42, wherein said TNF binding protein is non-glycosylated.
  - 52. The dosage unit according to claim 42, wherein said TNF binding protein is glycosylated.
- 53. The dosage unit according to claim 45, wherein an additional amino acid is added to the sequence of SEQ ID NO: 2 and the additional amino acid is an N-terminal methionine having the residue number "0".
- 54. The dosage unit according to claim 42, wherein said TNF binding protein is produced by recombinant DNA methods.
- 55. The dosage unit according to claim 42, wherein said inflammatory disease is an inflammatory disease of a joint.
- 56. The dosage unit according to claim 42, wherein said inflammatory disease is rheumatoid arthritis.

- 57. A pharmaceutical composition, comprising a TNF binding protein and a COX2 inhibitor for the treatment of an acute or chronic inflammatory disease in a patient.
- 58. The pharmaceutical composition according to claim 57 wherein the COX2 inhibitor is celecoxib.
- 59. The pharmaceutical composition according to claim 57, wherein the acute or chronic inflammatory disease is a TNF-mediated disease.
- 60. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 80% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 61. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 90% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 62. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 95% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 63. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises a sequence which is at least about 99% homologous to the amino acid sequence of SEQ ID NO: 2 or to the amino acid sequence of SEQ ID NO: 4.
- 64. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises an amino acid having a sequence of SEQ ID NO: 2.
- 65. The pharmaceutical composition according to claim 57, wherein said TNF binding protein comprises an N-terminal or C-terminal deletion of SEQ ID NO: 2.
- 66. The pharmaceutical composition according to claim 57, wherein said TNF binding protein is non-glycosylated.
- 67. The pharmaceutical composition according to claim 57, wherein said TNF binding protein is glycosylated.
- 68. The pharmaceutical composition according to claim 60, wherein an additional amino acid is added to the sequence of SEQ ID NO: 2 and the additional amino acid is an N-terminal methionine having the residue number "0".
- 69. The pharmaceutical composition according to claim 57, wherein said TNF binding protein is produced by recombinant DNA methods.
- 70 The pharmaceutical composition according to claim 57, wherein said inflammatory disease is an inflammatory disease of a joint.

71. The pharmaceutical composition to claim 57, wherein said inflammatory disease is rheumatoid arthritis.

The applicant requests submission of these amendments. The Commissioner is hereby authorized to charge any fees which may be required or credit any overpayment to Deposit Account No. 01-0519 in the name of Amgen Inc.

Respectfully submitted,

Timothy J. Gaul Attorney for Applicants Registration No.: 33,111 Phone: (805) 447-2688 Date: July 17,2001

Please send all future correspondence to:

U.S. Patent Operations/ TJG Dept. 4300, M/S 27-4-A AMGEN INC. One Amgen Center Drive Thousand Oaks, California 91320-1799

## VERSION WITH MARKINGS TO SHOW CHANGES MADE

This application is a division of application Serial No. 09/326,394 filed June 4, 1999, which is a continuation of PCT/US97/22733, filed December 8, 1997, which claims benefit to U.S. Provisional Serial No. 60/032,587, filed December 6, 1996, U.S. Provisional Serial No. 60/03,355, filed January 23, 1997, U.S. Provisional Serial No. 60/039,315, filed February 7, 1997 and U.S. Provisional Serial No. 60/052,023, filed July 9, 1997, all of which are hereby incorporated by reference.